GALR2 has potential as a therapeutic target in treating insulin resistance, as its activation alleviates insulin resistance through the P38MAPK/PGC-1α/GLUT4 and AKT/AS160/GLUT4 pathways in mouse skeletal muscle. Here, TBC1D4 is linked to Insulin resistance.